Therapeutic value and long-term safety of pulsed estrogen therapy

Maturitas

Volumn 38, Issue SUPPL.1, 2001, Pages

  Dören, Martina ^a   Al Azzawi, Farook ^b   Donnez, Jacques ^c   Van Der Mooren, Marius Jan ^d   Villero, José ^e   Gompel, Anne ^f  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HÔTEL DIEU   (France)

Author keywords

Endometrial safety; Estradiol nasal spray; Menopausal symptoms; Pulsed estrogen therapy; Withdrawal bleeding

Indexed keywords

ESTRADIOL;

AEROSOL; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SAFETY; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; AEROSOLS; DOUBLE-BLIND METHOD; ENDOMETRIAL HYPERPLASIA; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; SAFETY; TREATMENT OUTCOME;

EID: 10644246063     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0378-5122(01)00201-8     Document Type: Article

References (32)

1. Kupperman KI, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953;13:688-703.
2. Belchetz PE. Hormonal treatment of postmenopausal women. New Engl J Med 1994;330:1062-71.
3. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353:571-80.
4. Christiansen GA, Christensen MS, McNair P, Hagen C, Stocklund KE, Transbol I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9.
5. Michaelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. Br Med J 1998;316:1858-63.
6. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New Engl J Med 1996;335:453-61.
7. De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536-41.
8. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35(Suppl.):18S-24S.
9. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994;83:5-11.
10. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988;159:1540-6.
11. Frenkel Y, Kopernik G, Lazer S, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31-6.
12. The Transdermal HRT Investigators Group. A randomized study to compare the effectiveness, tolerability and acceptability of two different transdermal estradiol replacement therapies. Int J Fertil Menopausal Stud 1993;38:5-11.
13. Devissaguet JP, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17β-estradiol (S 21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 1999;24:265-71.
14. Scott RT, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758-64.
15. Studd J, Pornel B, Marton I, et al. Efficacy and acceptability of intranasal 17β-oestradiol for menopausal symptoms: randomised dose-response study. Lancet 1999;353:1574-8.
16. Mattsson LA, Christiansen C, Colau J-C, et al. Clinical equivalence of intranasal and oral 17β-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 2000;182:545-52.
17. Wiklund I, Karlberg J, Mattsson LA. Qualtity of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824-30.
18. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. Br Med J 1996;313:36-9.
19. Gompel A, Bergeron C, Jondet M, et al. Endometrial safety and tolerability of Aerodiol® intranasal estradiol for 1 year. Maturitas 2000;36:209-15.
20. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1994;20:91-9.
21. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998;5:226-9.
22. Bjorn I, Backsrom T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86.
23. Ettinger B, Pressman A. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy. Am J Manage Care 1999;5:779-85.
24. Christensen M, Hagen C, Christiansen C, Transbol IB. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982;144:873-9.
25. Steingold KA, Laufer L, Chetkowski J, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-32.
26. Studd JWW, McCarthy K, Zemblera D, et al. Efficacy and tolerance of Menorest®, compared to Premarin® in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study. Maturitas 1995;22:105-14.
27. Bacchi-Modena A, Bolis P, Campagnoli C, et al. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch. Maturitas 1997;27:285-92.
28. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994;170:1213-23.
29. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. J Am Med Assoc 1996;275:370-75.
30. Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in postmenopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas 1997;26:219-26.
31. Dören M, Schneider HPG. The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 1996;41(Suppl. 1):362-71.
32. Pelissier C, de Kervasdoue A, Chuong VT, et al. Clinical evaluation, dose-finding and acceptability of Aerodiol®, the pulsed. Estrogen therapy for treatment of climacteric symptoms. Maturitas 2001;37:181-9.